Literature DB >> 8192452

Effect of sucralfate on absorption of norfloxacin and ofloxacin.

P Lehto1, K T Kivistö.   

Abstract

The effect of sucralfate on the pharmacokinetics of norfloxacin and ofloxacin was assessed in two separate crossover studies with healthy volunteers. In both studies, eight subjects were randomized to one of the following three regimens: a 400-mg dose of norfloxacin or ofloxacin alone, norfloxacin or ofloxacin given simultaneously with sucralfate (1 g), or norfloxacin or ofloxacin given 2 h before sucralfate. Coadministration of sucralfate reduced the bioavailability of norfloxacin and ofloxacin by 91% (P < 0.001) and 61% (P < 0.001), respectively. However, when norfloxacin and ofloxacin were given 2 h before sucralfate, there were no significant alterations in the pharmacokinetics of either fluoroquinolone. Similar results were obtained when the cumulative amount of each fluoroquinolone recovered in the urine was used to calculate bioavailability. To avoid these interactions and potential therapeutic failures, norfloxacin and ofloxacin should not be used concurrently with sucralfate. The interaction can be minimized by maximizing the time between the fluoroquinolone dose and the previous sucralfate dose and giving the fluoroquinolone at least 2 h before another sucralfate dose.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8192452      PMCID: PMC284435          DOI: 10.1128/AAC.38.2.248

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Sucralfate.

Authors:  D M McCarthy
Journal:  N Engl J Med       Date:  1991-10-03       Impact factor: 91.245

2.  The effect of sucralfate pretreatment on the pharmacokinetics of ciprofloxacin.

Authors:  D E Nix; W A Watson; L Handy; R W Frost; D L Rescott; H R Goldstein
Journal:  Pharmacotherapy       Date:  1989       Impact factor: 4.705

3.  Clinical and chemical interactions between iron preparations and ciprofloxacin.

Authors:  M Kara; B B Hasinoff; D W McKay; N R Campbell
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 4.  Drug interactions with quinolones.

Authors:  H Lode
Journal:  Rev Infect Dis       Date:  1988 Jan-Feb

5.  A simple isocratic high-pressure liquid chromatographic assay of quinolones in serum.

Authors:  D J Griggs; R Wise
Journal:  J Antimicrob Chemother       Date:  1989-09       Impact factor: 5.790

6.  Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin.

Authors:  D E Nix; W A Watson; M E Lener; R W Frost; G Krol; H Goldstein; J Lettieri; J J Schentag
Journal:  Clin Pharmacol Ther       Date:  1989-12       Impact factor: 6.875

Review 7.  Drug interactions with quinolones.

Authors:  R Janknegt
Journal:  J Antimicrob Chemother       Date:  1990-11       Impact factor: 5.790

8.  Inhibition of enoxacin absorption by antacids or ranitidine.

Authors:  T H Grasela; J J Schentag; A J Sedman; J H Wilton; D J Thomas; R W Schultz; M E Lebsack; A W Kinkel
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

9.  Effect of sucralfate on pharmacokinetics of fleroxacin in healthy volunteers.

Authors:  T J Lubowski; C H Nightingale; K Sweeney; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

10.  Sucralfate significantly reduces ciprofloxacin concentrations in serum.

Authors:  J C Garrelts; P J Godley; J D Peterie; E H Gerlach; C C Yakshe
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

View more
  18 in total

1.  Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers.

Authors:  H Stass; U Schühly; J G Möller; H Delesen
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

2.  Influence of intravenously administered ciprofloxacin on aerobic intestinal microflora and fecal drug levels when administered simultaneously with sucralfate.

Authors:  W A Krueger; G Ruckdeschel; K Unertl
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

Review 3.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 4.  Clinical Drug-Drug Pharmacokinetic Interaction Potential of Sucralfate with Other Drugs: Review and Perspectives.

Authors:  Suresh P Sulochana; Muzeeb Syed; Devaraj V Chandrasekar; Ramesh Mullangi; Nuggehally R Srinivas
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-10       Impact factor: 2.441

Review 5.  Pharmacokinetics and pharmacodynamics of fluoroquinolones.

Authors:  J Turnidge
Journal:  Drugs       Date:  1999       Impact factor: 9.546

6.  Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects.

Authors:  L J Lee; B Hafkin; I D Lee; J Hoh; R Dix
Journal:  Antimicrob Agents Chemother       Date:  1997-10       Impact factor: 5.191

Review 7.  Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.

Authors:  S V Onrust; H M Lamb; J A Balfour
Journal:  Drugs       Date:  1998-11       Impact factor: 9.546

8.  Relationship of quantitative structure and pharmacokinetics in fluoroquinolone antibacterials.

Authors:  Die Cheng; Wei-Ren Xu; Chang-Xiao Liu
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

Review 9.  Absorption interactions with fluoroquinolones. 1995 update.

Authors:  B M Lomaestro; G R Bailie
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

10.  Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.

Authors:  Payam Nahid; Susan E Dorman; Narges Alipanah; Pennan M Barry; Jan L Brozek; Adithya Cattamanchi; Lelia H Chaisson; Richard E Chaisson; Charles L Daley; Malgosia Grzemska; Julie M Higashi; Christine S Ho; Philip C Hopewell; Salmaan A Keshavjee; Christian Lienhardt; Richard Menzies; Cynthia Merrifield; Masahiro Narita; Rick O'Brien; Charles A Peloquin; Ann Raftery; Jussi Saukkonen; H Simon Schaaf; Giovanni Sotgiu; Jeffrey R Starke; Giovanni Battista Migliori; Andrew Vernon
Journal:  Clin Infect Dis       Date:  2016-08-10       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.